Enzyme therapy for the lysosomal storage disorders: Principles, patents, practice and prospects

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 8, 2003, Pages 1157-1172

  Pastores, Gregory M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Enzyme therapy; Fabry disease; Gaucher disease; GSD II (Pompe disease); Lysosomal storage disorder (LSD); MPS I (Hurler Scheie syndrome)

Indexed keywords

ACID LIPASE; AGALSIDASE ALFA; AGALSIDASE BETA; ALGLUCERASE; ALPHA GALACTOSIDASE; ALPHA GLUCOSIDASE; BETA GLUCOSIDASE; BETA N ACETYLHEXOSAMINIDASE A; CERAMIDE DERIVATIVE; ENZYME INHIBITOR; GALECTIN; GLUCOSYLCERAMIDASE; GLUCOSYLTRANSFERASE; HYDROLASE; IMIGLUCERASE; LARONIDASE; LEVO IDURONIDASE; MIGLUSTAT; NEUROTROPHIC FACTOR; NOJIRIMYCIN; OSTEONECTIN; OSTEOPONTIN; PALMATINE; PIPERIDINE DERIVATIVE; PLACENTA ENZYME; PROPANOL; PROTEINASE; PROTEINASE INHIBITOR; RECOMBINANT ENZYME; SULFATASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BIOCHEMISTRY; BIOTECHNOLOGY; BONE MARROW TRANSPLANTATION; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME LOCALIZATION; ENZYME THERAPY; FABRY DISEASE; FINANCIAL MANAGEMENT; GAUCHER DISEASE; GENE EXPRESSION; GENE THERAPY; GENETICS; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LONG TERM CARE; LYSOSOME STORAGE DISEASE; MEDICAL RESEARCH; MOLECULAR MECHANICS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATENT; QUALITY OF LIFE; REVIEW; VIRAL GENE DELIVERY SYSTEM;

EID: 0042027843     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.8.1157     Document Type: Review

References (101)

1. KARAGEORGOS LE, ISAAC EL, BROOKS DA et al.: Lysosomal biogenesis in lysosomal storage disorders. Exp. Cell Res. (1997) 234(1):85-97.
2. KOLTER T, DOERING T, WILKENING G, WERTH N, SANDHOFF K: Recent advances in the biochemistry of glycosphingolipid metabolism. Biochem. Soc. Trans. (1999) 27(4):409-415.
3. WRAITH JE: Lysosomal disorders. Semin. Neonatol. (2002) 7(1):75-83.
4. BEIGHTON G, BEIGHTON P: The person behind the syndrome (revised edn), Springer Verlag, Berlin, Germany (1997).
5. MEIKLE PJ, HOPWOOD JJ, CLAGUE AE, CAREY WF: Prevalence of lysosomal storage disorders. JAMA (1999) 281:249-254.
6. JEYAKUMAR M, BUTTERS TD, DWEK RA, PLATT FM: Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Neuropathol. Appl. Neurobiol. (2002) 28(5):343-357.
7. SCHIFFMANN R, BRADY RO: New prospects for the treatment of lysosomal storage diseases. Drugs (2002) 62(5):733-742.
8. DEDUVE C: From cytases to lysosomes. Fed. Proc. (1964) 23:1045-1049.
9. BRADY RO: The sphingolipidoses. N. Engl. J. Med. (1966) 275(6):312-318.
10. HOBBS JR, HUGH-JONES K, BARRETT AJ et al.: Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet (1981) 2(8249):709-712.
11. RAPPEPORT JM, GINNS EI: Bone-marrow transplantation in severe Gaucher's disease. N. Engl. J. Med. (1984) 311(2):84-88.
12. KRIVIT W: Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv. Pediatr. (2002) 49:359-378.
13. GOODWIN CD: Technology transfer at US universities: seeking public benefit from the results of basic research. Technol. Health Care. (1996) 4(3):323-330.
14. HAFFNER ME, WHITLEY J, MOSES M: Two decades of orphan product development. Nat. Rev. Drug Discov. (2002) 1(10):821-825.
15. DWEK RA, BUTTERS TD, PLATT FM, ZITZMANN N: Targeting glycosylation as a therapeutic approach. Nat. Rev. Drug. Discov. (2002) 1(1):65-75.
16. FRUSTACI A, CHIMENTI C, RICCI R et al.: Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N. Engl. J. Med. (2001) 345(1):25-32.
17. KAYE EM, SENA-ESTEVES M: Gene therapy for the central nervous system in the lysosomal storage disorders. Neurol. Clin. (2002) 20(3):879-901.
18. PASTORES GM, BARNETT NL: Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease Type 1. Expert Opin. Investig. Drugs (2003) 12(2):273-281.
19. DESNICK RJ, SCHUCHMAN EH: Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat. Rev. Genet. (2002) 3(12):954-966.
20. BARRANGER JM, NOVELLI EA: Gene therapy for lysosomal storage disorders. Expert Opin. Biol. Ther. (2001) 1(5):857-867.
21. KAYE EM: Therapeutic approaches to lysosomal storage diseases. Curr. Opin. Pediatr. (1995) 7(6):650-654.
22. DAMIANO AM, PASTORES GM, WARE JE Jr: The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study. Qual. Life Res. (1998) 7(5):373-386.
23. GOLD KF, PASTORES GM, BOTTEMAN MF: Quality of life of patients with Fabry disease. Qual. Life Res. (2002) 11(4):317-327.
24. STAHL PD, RODMAN JS, MILLER MJ, SCHLESINGER PH: Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc. Natl. Acad. Sci. USA (1978) 75(3):1399-1403.
25. STOCKERT RJ, MORELL AG, ASHWELL G: Structural characteristics and regulation of the asialoglycoprotein receptor. Targeted Diagn. Ther. (1991) 4:41-64.
26. DAHMS NM, HANCOCK MK: P-type lectins. Biochim. Biophys. Acta (2002) 1572(2-3):317-340.
27. SLY WS: Enzyme replacement therapy: from concept to clinical practice. Acta Paediatr. Suppl. (2002) 91(439):71-78.
28. BOU-GHARIOS G, ABRAHAM D, OLSEN I: Lysosomal storage diseases: mechanisms of enzyme replacement therapy. Histochem. J. (1993) 25(9):593-605.
29. KRETZMER G: Industrial processes with animal cells. Appl. Microbiol. Biotechnol. (2002) 59(2-3):135-142.
30. SUZUKI K, PROIA RL, SUZUKI K: Mouse models of human lysosomal diseases. Brain Pathol. (1998) 8(1):195-215.
31. SUZUKI K, MANSSON JE: Animal models of lysosomal disease: an overview. J. Inherit. Metab. Dis. (1998) 21(5):540-547.
32. BOWERS WE, DE DUVE C: Lysosomes in lymphoid tissue. II. Intracellular distribution of acid hydrolases. J. Cell. Biol. (1967) 32(2):339-348.
33. DE BARSY T, HERS HG: Normal metabolism and disorders of carbohydrate metabolism. Baillieres Clin. Endocrinol. Metab. (1990) 4(3):499-522.
34. BRADY RO: Therapy for the sphingolipidoses. Arch. Neurol. (1998) 55(8):1055-1056.
35. FRATANTONI JC, HALL CW, NEUFELD EF: Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science (1968) 162(853):570-572.
36. KAPLAN A, FISCHER D, ACHORD D, SLY W: Phosphohexosyl recognition is a general characteristic of pinocytosis of lysosomal glycosidases by human fibroblasts. J. Clin. Invest. (1977) 60(5):1088-1093.
37. KORNFELD S: Structure and function of the mannose 6-phosphate/insulin-like growth factor II receptors. Annu. Rev. Biochem. (1992) 61:307-330.
38. DESNICK RJ: Enzyme replacement and beyond. J. Inherit. Metab. Dis. (2001) 24(2):251-265.
39. NEUFELD EF: Lysosomal storage diseases. Ann. Rev. Biochem. (1991) 60:257-280.
40. LANG L, COUSO R, KORNFELD S: Glycoprotein phosphorylation in simple eucaryotic organisms. Identification of UDP-GlcNAc:glycoprotein N-acetylglucosamine-1-phosphotransferase activity and analysis of substrate specificity. J. Biol. Chem. (1986) 261(14):6320-6325.
41. MACH L: Biosynthesis of lysosomal proteases in health and disease. Biol. Chem. (2002) 383(5):751-756.
42. KRIVIT W, AUBOURG P, SHAPIRO E, PETERS C: Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Curr. Opin. Hematol. (1999) 6(6):377-382.
43. KRIVIT W, PETERS C, SHAPIRO EG: Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease Type III. Curr. Opin. Neurol. (1999) 12(2):167-176.
44. DEVINE SM, ADKINS DR, KHOURY H et al.: Recent advances in allogeneic hematopoietic stem-cell transplantation. J. Lab. Clin. Med. (2003) 141(1):7-32.
45. KAYLER LK, MERION RM, LEE S et al.: Long-term survival after liver transplantation in children with metabolic disorders. Pediatr. Transplant. (2002) 6(4):295-300.
46. SESSA A, MERONI M, BATTINI G et al.: Renal transplantation in patients with Fabry disease. Nephron. (2002) 91(2):348-351.
47. ARTLETT CM: Microchimerism in health and disease. Curr. Mol. Med. (2002) 2(6):525-535.
48. BRADY RO, BARTON NW: Enzyme replacement therapy for Gaucher disease: critical investigations beyond demonstration of clinical efficacy. Biochem. Med. Metab. Biol. (1994) 52(1):1-9.
49. TAYLOR ME: Recognition of complex carbohydrates by the macrophage mannose receptor. Biochem. Soc. Trans. (1993) 21(2):468-473.
50. GEFFEN I, SPIESS M: Asialoglycoprotein receptor. Int. Rev. Cytol. (1992) 137B: 181-219.
51. GRABOWSKI GA, BARTON NW, PASTORES G et al.: Enzyme therapy in Type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. (1995) 122(1):33-39.
52. FURBISH FS, STEER CJ, KRETT NL, BARRANGER JA: Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim. Biophys. Acta. (1981) 673(4):425-434.
53. MURRAY GJ, DOEBBER TW, SHEN TY et al.: Targeting of synthetically glycosylated human placental glucocerebrosidase. Biochem. Med. (1985) 34(2):241-246.
54. PASTORES GM, SIBILLE AR, GRABOWSKI GA: Enzyme therapy in Gaucher disease Type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood (1993) 82(2):408-416.
55. DE FOST M, AERTS JM, HOLLAK CE: Gaucher disease: from fundamental research to effective therapeutic interventions. Neth. J. Med. (2003) 61(1):3-8.
56. WEINREB NJ, CHARROW J, ANDERSSON HC et al.: Effectiveness of enzyme replacement therapy in 1028 patients with Type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. J. Med. (2002) 113(2):112-119.
57. ELSEA SH, LUCAS RE: The mousetrap: what we can learn when the mouse model does not mimic the human disease. ILAR J. (2002) 43(2):66-79.
58. WILLEMSEN R, TYBULEWICZ V, SIDRANSKY E et al.: A biochemical and ultrastructural evaluation of the Type 2 Gaucher mouse. Mol. Chem. Neuropathol. (1995) 24(2-3):179-192.
59. ZHAO H, GRABOWSKI GA: Gaucher disease: perspectives on a prototype lysosomal disease. Cell Mol. Life Sci. (2002) 59(4):694-707.
60. PASTORES GM, THADHANI R: Advances in the management of Anderson-Fabry disease: enzyme replacement therapy. Expert Opin. Biol. Ther. (2002) 2(3):325-333.
61. KAKKIS ED: Enzyme replacement therapy for the mucopolysaccharide storage disorders. Expert Opin. Investig. Drugs (2002) 11(5):675-685.
62. RABEN N, PLOTZP, BYRNE BJ: Acid α-glucosidase deficiency (glycogenosis Type II, Pompe disease). Curr. Mol. Med. (2002) 2(2):145-166.
63. MEIKLE PJ, HOPWOOD JJ, CLAGUE AE, CAREY WF: Prevalence of lysosomal storage disorders. JAMA (1999) 281(3):249-254.
64. The metabolic and molecular basis of inherited diseases (8th edn). Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York, USA (2001).
65. SCHIFFMANN R, MURRAY GJ, TRECO D: Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl. Acad. Sci. USA (2000) 97(1):365-370.
66. SCHIFFMANN R, KOPP JB, AUSTIN HA III et al.: Enzyme replacement therapy in Fabry disease: a randomised controlled trial. JAMA (2001) 285(21):2743-2749.
67. ENG CM, GUFFON N, WILCOX WR et al.: International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human α-galactosidase A-replacement therapy in Fabry's disease. N. Engl. J. Med. (2001) 345(1):9-16.
68. BARTON NW, BRADY RO, DAMBROSIA JM et al.: Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Eng. J. Med. (1991) 324(21):1464-1470.
69. BROOKS DA. α-L-Iduronidase and enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin. Biol. Ther. (2002) 2(8):967-976.
70. AMALFITANO A, BENGUR AR, MORSE RP et al.: Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease Type II: results of a Phase I/II clinical trial. Genet. Med. (2001) 3(2):132-138.
71. REUSER AJ, VAN DEN HOUT H, BIJVOET AG, KROOS MA, VERBEET MP, VAN DER PLOEG AT: Enzyme therapy for Pompe disease: from science to industrial enterprise. Eur. J. Pediatr. (2002) 161(Suppl.1):S106-S1011.
72. DEMETS DL: Clinical trials in the new millennium. Stat. Med. (2002) 21(19):2779-2787.
73. FLEMING TR, DEMETS DL: Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med. (1996) 125(7):605-613.
74. BROOKS DA: Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol. Genet. Metab. (1999) 68(2):268-275.
75. RABEN N, JATKAR T, LEE A et al.: Glycogen stored in skeletal but not in cardiac muscle in acid α-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol. Ther. (2002) 6(5):601-608.
76. PONCE E, MOSKOVITZ J, GRABOWSKI G: Enzyme therapy in Gaucher disease Type 1: effect of neutralizing antibodies to acid β-glucosidase. Blood (1997) 90(1):43-48.
77. IOANNOU YA, ZEIDNER KM, GORDON RE, DESNICK RJ: Fabry disease: preclinical studies demonstrate the effectiveness of α-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet. (2001) 68(1):14-25.
78. DVIR H, HAREL M, MCCARTHY AA, TOKER L: X-ray structure of human acid-β-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. (2003) 4(7):1-6.
79. THURBERG BL, RENNKE H, COLVIN RB et al.: Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. (2002) 62(6):1933-1946.
80. PAGANO RE: Endocytic trafficking of glycosphingolipids in sphingolipid storage diseases. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2003) 358(1433):885-891.
81. REID PC, SUGII S, CHANG TY: Trafficking defects in endogenously synthesized cholesterol in fibroblasts, macrophages, hepatocytes, and glial cells from Niemann-Pick type C1 mice. J. Lipid Res. (2003) 44(5):1010-1019.
82. LEE K, JIN X, ZHANG K et al.: A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology (2003) 13(4):305-313.
83. ROSENBERG M, KINGMA W, FITZPATRICK MA, RICHARDS SM: Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood (1999) 93(6):2081-2088.
84. BRADY RO, MURRAY GJ, OLIVER KL: Management of neutralizing antibody to Ceredase in a patient with Type 3 Gaucher disease. Pediatrics (1997) 100(6):E11.
85. VELLODI A, BEMBI B, DE VILLEMEUR TB et al.: Neuronopathic Gaucher disease task force of the european working group on gaucher disease. Management of neuronopathic Gaucher disease: a European consensus. J. Inherit. Metab. Dis. (2001) 24(3):319-327.
86. JEYAKUMAR M, THOMAS R, ELLIOT-SMITH E et al.: Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain (2003) 126(Pt 4):974-987.
87. MYEROWITZ R, LAWSON D, MIZUKAMI H, MI Y, TIFFT CJ, PROIA RL: Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum. Mol. Genet. (2002) II(11):1343-1350.
88. MIZUKAMI H, MI Y, WADA R et al.: Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J. Clin. Invest. (2002) 9(9):1215-1221.
89. MOORE DF, HERSCOVITCH P, SCHIFFMANN R: Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J. Neuroimaging (2001) 11(3):303-307.
90. MOORE DF; ALTARESCU A, LING GSF et al.: Cerebrovascular hyperdynamicity in Fabry disease with reversal following enzyme replacement therapy. Stroke (2002) 33(2):525-531.
91. MOORE DF, SCOTT IT, GLADWIN MT et al.: Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation (2001) 104(13):1506-1512.
92. PARDRIDGE WM: Targeting neurotherapeutic agents through the blood-brain barrier. Arch. Neurol. (2002) 59(1):35-40.
93. ZINBERG RE, KORNREICH R, EDELMANN L, DESNICK RJ: Prenatal genetic screening in the Ashkenazi Jewish population. Clin. Perinatol. (2001) 28(2):367-382.
94. MEIKLE PJ, RANIERI E, RAVENSCROFT EM, HUA CT, BROOKS DA, HOPWOOD JJ: Newborn screening for lysosomal storage disorders. Southeast Asian J. Trop. Med. Public Health (1999) 30(Suppl.2):104-110.
95. WALKLEY SU: New proteins from old diseases provide novel insights in cell biology. Curr. Opin. Neurol. (2001) 14(6):805-810.
96. ZERVAS M, SOMERS KL, THRALL MA, WALKLEY SU: Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr. Biol. (2001) 11(16):1283-1287.
97. MILLAT G, CHIKH K, NAURECKIENE S, SLEAT DE et al.: Niemann-Pick disease type C: spectrum of HE1 mutations and genotype/phenotype correlations in the NPC2 group. Am. J. Hum. Genet. (2001) 69(5):1013-1021.
98. ANDERSON GF, RELNHARDT UE, HUSSEY PS, PETROSYAN V: It's the prices, stupid: why the United States is so different from other countries. Health Aff. (Millwood). (2003) 22(3):89-105.
99. The World Health Report. World health organisation, Geneva, Switzerland (2002).
100. YANG W, HAAN K: Strategy: making Genzyme bigger. Biotech. Century (2003) 11(10):2193-2203.
101. WAGER E: How to dance with porcupines: rules and guidelines on doctors' relations with drug companies. Br. Med. J. (2003) 326(7400):1196-1198.